awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F
Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
P2860
Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37919869-AE07342F-7FC0-4511-B670-EF6EAF709D7F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
aafd389102116855f6443522679cbd86dc483191
P2860
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.